Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies

Mechanisms of resistance to CAR T cell therapies

Resistance and recurrence of malignancies after CAR-T cell therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

New development in CAR-T cell therapy

Creutzfeldt-Jakob disease manifesting as posterior cortical dementia

Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Relapse after CAR-T Cell Therapy in B-cell Malignancies: Challenges and Future Approaches

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Challenges and strategies associated with CAR-T cell therapy in blood malignancies

[Chemotherapy of gynecologic tumors].